

# Johnson & Johnson Innovative Medicine Pipeline

## Key Events in 2026\*

### POTENTIAL APPROVALS US/EU

US	<b>TREMFYA (guselkumab)</b> Psoriatic Arthritis Structural Damage (APEX)
✓ US EU	<b>ICOTYDE (icetrotinra)</b> Psoriasis (ICONIC)
EU	<b>AKEEGA (niraparib/abiraterone)</b> M1 Metastatic Castration-Sensitive Prostate Cancer (AMPLITUDE)
✓ US	<b>DARZALEX (daratumumab)</b> Frontline multiple myeloma transplant ineligible (CEPHEUS)
✓ US EU	<b>TECVAYLI (teclistamab)</b> Multiple Myeloma 1-3PLs (MajesTEC-3)
EU	<b>TECVAYLI (teclistamab)</b> Relapsed Refractory Multiple Myeloma CD38 exposed (MajesTEC-9)

### PLANNED SUBMISSIONS US/EU

✓ US	<b>nipocalimab</b> Warm Autoimmune Hemolytic Anemia (ENERGY)
US	<b>CAPLYTA (lumateperone)</b> Bipolar Mania
US EU	<b>ERLEADA (apalutamide)</b> Localized Prostate Cancer (ATLAS)
US EU	<b>ERLEADA (apalutamide)</b> High Risk Prostate Cancer (PROTEUS)
US	<b>bleximenib</b> Relapsed Refractory Acute Myeloid Leukemia (cAMeLot-1)
✓ US ✓ EU	<b>TALVEY (talquetamab)</b> Relapsed Refractory Multiple Myeloma A-CD38 Naïve (MonumenTAL-3)
✓ US ✓ EU	<b>TECVAYLI (teclistamab)</b> Relapsed Refractory Multiple Myeloma CD38 exposed (MajesTEC-9)
✓ EU	<b>TECVAYLI (teclistamab)</b> Multiple Myeloma 1-3PLs (MajesTEC-3)
US EU	<b>INLEXZO (gemcitabine intravesical delivery system)</b> High Risk Non Muscle Invasive Bladder Cancer BCG Experienced (SunRISe-5)

### POTENTIAL CLINICAL DATA PRESENTATIONS<sup>1</sup>

#### Phase III

✓	<b>ICOTYDE (icetrotinra)</b> Psoriasis (ICONIC-ADVANCE 1&2 Update)	<b>ERLEADA (apalutamide)</b> Localized Prostate Cancer (ATLAS)	<b>JNJ-4804 Co-antibody Therapy</b> Ulcerative Colitis (DUET-UC)
	<b>ICOTYDE (icetrotinra)</b> Psoriasis (ICONIC-ASCEND)	<b>ERLEADA (apalutamide)</b> High Risk Prostate Cancer (PROTEUS)	<b>JNJ-4804 Co-antibody Therapy</b> Crohn's Disease (DUET-CD)
	<b>icetrotinra</b> Psoriatic Arthritis (ICONIC-PsA)	<b>TALVEY (talquetamab)</b> Relapsed Refractory Multiple Myeloma A-CD38 Naïve (MonumenTAL-3)	<b>JNJ-4804 Co-antibody Therapy</b> Psoriatic Arthritis (AFFINITY)
	<b>ICOTYDE (icetrotinra)</b> Psoriasis (ICONIC-TOTAL Update)	<b>TECVAYLI (teclistamab)</b> Relapsed Refractory Multiple Myeloma CD38 exposed (MajesTEC-9)	<b>nipocalimab</b> Systemic Lupus Erythematosus (JASMINE)
	<b>CAPLYTA (lumateperone)</b> Bipolar Mania (ITI-007-452)	<b>INLEXZO (gemcitabine intravesical delivery system)</b> High Risk Non Muscle Invasive Bladder Cancer BCG Experienced (SunRISe-5)	<b>bleximenib</b> Relapsed Refractory Acute Myeloid Leukemia (cAMeLot-1)
	<b>nipocalimab</b> Warm Autoimmune Hemolytic Anemia (ENERGY)		<b>JNJ-1887 sCD59</b> Geographic Atrophy (PARASOL)

#### Phase I/ II

1. In order to be on key events clinical presentation, data must be presented at a major medical meeting.

✓ = Achieved

\*This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs and assets and does not guarantee continued investment. This information is as of April 14, 2026 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.